BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang H, Zhang W, Jiang L, Chen Y. Recent advances in systemic therapy for hepatocellular carcinoma. Biomark Res 2022;10:3. [PMID: 35000616 DOI: 10.1186/s40364-021-00350-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Brandt EF, Baues M, Wirtz TH, May J, Fischer P, Beckers A, Schüre B, Sahin H, Trautwein C, Lammers T, Berres M. Chemokine CXCL10 Modulates the Tumor Microenvironment of Fibrosis-Associated Hepatocellular Carcinoma. IJMS 2022;23:8112. [DOI: 10.3390/ijms23158112] [Reference Citation Analysis]
2 Guo Z, Li H, Shiao Y. Editorial: Biomarkers of Immune-Checkpoint-Inhibitor Immunotherapies in Hepatocellular Carcinomas. Front Oncol 2022;12:860964. [DOI: 10.3389/fonc.2022.860964] [Reference Citation Analysis]
3 Zhu X, Zhang Y, Wu Y, Diao W, Deng G, Li Q, Wu C. HMOX1 Attenuates the Sensitivity of Hepatocellular Carcinoma Cells to Sorafenib via Modulating the Expression of ABC Transporters. Int J Genomics 2022;2022:9451557. [PMID: 35800617 DOI: 10.1155/2022/9451557] [Reference Citation Analysis]
4 Sun J, Wang J, Li T, Ma Y, Xue D, Chen J. Design and synthesis of ludartin derivatives as potential anticancer agents against hepatocellular carcinoma. Med Chem Res. [DOI: 10.1007/s00044-022-02890-2] [Reference Citation Analysis]
5 Sauzeau V, Beignet J, Vergoten G, Bailly C. Overexpressed or hyperactivated Rac1 as a target to treat hepatocellular carcinoma. Pharmacol Res 2022;:106220. [PMID: 35405309 DOI: 10.1016/j.phrs.2022.106220] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Digiacomo G, Fumarola C, La Monica S, Bonelli M, Cavazzoni A, Galetti M, Terenziani R, Eltayeb K, Volta F, Zoppi S, Bertolini P, Missale G, Alfieri R, Petronini PG. CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells. Front Oncol 2022;12:942341. [DOI: 10.3389/fonc.2022.942341] [Reference Citation Analysis]
7 Moustafa M, Dähling K, Günther A, Riebandt L, Smit DJ, Riecken K, Schröder C, Zhuang R, Krech T, Kriegs M, Fehse B, Izbicki JR, Fischer L, Nashan B, Li J, Jücker M. Combined Targeting of AKT and mTOR Inhibits Tumor Formation of EpCAM+ and CD90+ Human Hepatocellular Carcinoma Cells in an Orthotopic Mouse Model. Cancers 2022;14:1882. [DOI: 10.3390/cancers14081882] [Reference Citation Analysis]